The Directorate General of Trade Remedies (DGTR), under the Ministry of Commerce & Industry, has scheduled a public oral hearing as part of its ongoing anti-dumping investigation into imports of Monoisopropylamine (MIPA) from China. The investigation, initiated on December 30, 2024, aims to determine whether Chinese MIPA imports are being unfairly priced and whether they are causing material injury to the Indian industry. MIPA is a key chemical used in the production of active pharmaceutical ingredients (APIs) and drug formulations.

The oral hearing will be held on July 16, 2025, at 3:00 PM (IST) in hybrid mode—participants can join in person at the DGTR Conference Room, Jeevan Tara Building, New Delhi, or virtually via Digital Video Conferencing (DVC). A list of registered interested parties eligible to attend is available on the DGTR’s official website. All participants must submit their details, including organizational affiliation, contact information, and preferred mode of participation, by July 15, 2025.

As per procedural guidelines, any party intending to present documents at the hearing must circulate copies to all participants at least one day before the hearing. For submissions containing confidential information, a non-confidential version (NCV) must be submitted to the Designated Authority at least three days before the hearing. The NCV must be a meaningful summary of the confidential content. Failure to comply may lead to the party being disallowed from presenting the information.